SynthesisBMC infectious diseases2025
Risk of drug-induced liver injury in chronic hepatitis C and tuberculosis co- infection: a systematic review and meta- analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis of risk prediction models for anti-tuberculosis drug-induced liver injury in East Asian populations.Frontiers in public health · 2026Pooled it
- HBV/HCV coinfection and anti-tuberculosis drug-induced liver injury: from risk assessment and exploration of mechanisms to preventive considerations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Exploring the partial immunological mechanisms of hepatitis B virus reactivation in patients with hepatitis B and tuberculosis.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeAntituberculosis drug-induced liver injury (ATLI) is a common and serious adverse drug reaction of tuberculosis treatment. The impact of ATLI in patients with chronic hepatitis C is unclear. The aim of this study is to evaluate the prevalence of DILI in patients with and without HCV and assess its impact in the prevalence of ATLI.
methodsThe preferred reporting items for systematic reviews and meta-analyses standards were followed, and the protocol was registered in PROSPERO. In this study, PubMed, Web of Sciences, EMBASE, the Cochrane Library were searched from inception to 21 May 2024. We performed a systematic review and meta-analysis of studies of the papers relevant to compare the prevalence of anti-tuberculosis drug-induced liver injury in patients with and without chronic hepatitis C. Subgroup analyses were predefined for DILI severity (mild/moderate/severe), diagnostic criteria (ALT > 3ULN vs. >5ULN), anti-TB regimens (3-drug vs. 4-drug), HCV definition (antibody vs. RNA positivity), and study design (prospective vs. retrospective).
resultsThirteen studies comprising a total of 3,174 patients met the inclusion criteria and were included in the final analysis. Of these, 727 patients had HCV-TB co-infection, while 2,447 presented with active TB infection without HCV. The overall prevalence of DILI in patients with HCV-TB was 15.54% and 8.54% in patients without HCV(OR = 3.50, 95% CI 2.48-4.94,I
conclusionThis meta-analysis suggests that the prevalence of DILI in patients with HCV is higher than in those without HCV. Routine HCV screening before the initiation of TB therapy is critically important for the early identification of HCV-TB co-infection, enabling clinicians to modify TB and HCV treatment and management to mitigate the risks of DILI. Close follow-up and regular liver test monitoring are indispensable for the treatment of TB in chronic hepatitis C carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.